EP1931679A4 - Analogs of salinosporamide a - Google Patents
Analogs of salinosporamide aInfo
- Publication number
- EP1931679A4 EP1931679A4 EP06789692A EP06789692A EP1931679A4 EP 1931679 A4 EP1931679 A4 EP 1931679A4 EP 06789692 A EP06789692 A EP 06789692A EP 06789692 A EP06789692 A EP 06789692A EP 1931679 A4 EP1931679 A4 EP 1931679A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- substituted
- unsubstituted
- group
- butyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Salinosporamide A (1) was discovered by Fenical et al. as a bioactive product of a marine microorganism that is widely distributed in ocean sediments. See, Fenical et al., Angew. Chem. Int. Ed., 2003, 42, 355-357. More recently, a simple stereocontrolled total synthesis of salinosporamide A was reported by Corey et al., J. Amer. Chem. Soc, 2004, 126 (20) 6230-6231.
- Salinosporamide A inhibits the proteasome, an intracellular enzyme complex that destroys proteins the cell no longer needs. Without the proteasome, proteins would build up and clog cellular machinery. Fast-growing cancer cells make especially heavy use of the proteasome, so thwarting its action is a compelling drug strategy. See, Fenical et al., U.S. Patent Publication No. 2003-0157695A1, the disclosure of which is hereby incorporated herein by reference.
- One embodiment of the present invention comprises nucleophilic substituted analogs of Salinosporamide A, having the Formula I:
- R 1 is selected from the group consisting of substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C2-C8 alkenyl, substituted or unsubstituted C2-C8 alkynyl, substituted or unsubstituted, saturated or unsaturated, C3-C8 cycloalkyl, benzyl and substituted benzyl; wherein the substituent groups are independently selected from the group consisting of Cl- C4 alkoxy, amido, and halogen;
- R 2 is selected from the group consisting of substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C2-C8 alkenyl, substituted or unsubstituted C2-C8 alkynyl, substituted or unsubstituted, saturated or unsaturated, C3-C8 cycloalkyl, benzyl and substituted benzyl; wherein the substituent groups are independently selected from the group consisting of Cl- C4 alkoxy, amido, halogen and aryl; and
- Nu is a nucleophile
- R 1 is preferably selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, and tert-butyl, each optionally substituted by halogen, preferably selected from Cl and F.
- R 1 is preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, each optionally with a double bond.
- R 2 is preferably selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl, each optionally substituted by one or more substituents selected from the group consisting of C1-C4 alkoxy, amido, halogen and aryl.
- Preferred halogens are Cl and F.
- Nu is preferably selected from the group consisting of Iodide (I-), Hydrogen Sulfide (HS-), Carb-sulfides (RS-); Bromide (Br-), Hydroxide (HO-), Carb- oxides (RO-), Cyanide (CN-), Azide (N3-); Amine (NH2-), Carb-amines (-NHR), Chloride (Cl-), Fluoride (F-), and Carboxylates (RCO2-).
- the R groups are independently selected from the group consisting of substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C2-C8 alkenyl, substituted or unsubstituted C2-C8 alkynyl, substituted or unsubstituted, saturated or unsaturated, C3- C8 cycloalkyl, benzyl and substituted benzyl; wherein the substituent groups are independently selected from the group consisting of C1-C4 alkoxy, amido, halogen and aryl.
- Another embodiment of the present invention provides synthetic methods for the - A - formation of the compounds of Formula I and intermediate compounds associated therewith.
- Another embodiment of the present invention is the compound (+) dihydro- salinosporamide A, having the Formula II:
- Another embodiment of the present invention provides a synthetic method for the formation of the compound of Formula II and intermediate compounds associated therewith.
- Another embodiment of the present invention comprises the treatment of mammalian, preferably human, diseases with the compounds of the present invention.
- the compounds of the present invention are expected to possess the same range of activities exhibited by Salinosporamide A and the other related compounds, such as omuralide, lactacystin and the known analogs of lactacystin and clasto-lactacystin beta- lactone. See, Masse et al., Eur. J. Org. Chem., 2000, 2513-2528.
- Figure 1 is a synthetic scheme (Scheme I) for the preparation of the compounds of Formula I.
- Figure 2 is a synthetic scheme (Scheme II) for the preparation of the compounds of Formula II.
- Figure 3 is a synthetic scheme (Scheme III) for the preparation of intermediate compounds useful in the synthesis of the compounds of Formula I and Formula II.
- Figure 4 illustrates Scheme IV, a racemic synthesis route for compounds of the present invention.
- Figure 5 in parts A and B respectively, compares the 1 H NMR scans of authentic 7,8-dihydrosalinosporamide with synthetic (+)7,8-dihydrosalinosporamide.
- Figure 6 provides details regarding the determination of the relative stereochemistry of the iodide intermediate made from Compound 8.
- Figure 7 provides details of Scheme V, in two parts (Part 1 and Part 2), the enantioselective synthesis of Salinosporamide A analogs of the present invention.
- nucleophilic substituted analogs of Salinosporamide A having the formula:
- Nu is selected from the group consisting of Iodide (I-), Hydrogen Sulfide (HS-), Carb-sulfides (RS-); Bromide (Br-), Hydroxide (HO-), Carb-oxides (RO-), Cyanide (CN-), Azide (N 3 -); Amine (NH 2 -), Carb-amines (-NHR), Chloride (Cl-), Fluoride (F-), and Carboxylates (RCO-).
- the R groups are independently selected from the group consisting of substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C2-C8 alkenyl, substituted or unsubstituted C2-C8 alkynyl, substituted or unsubstituted, saturated or unsaturated, C3-C8 cycloalkyl, benzyl and substituted benzyl; wherein the substituent groups are independently selected from the group consisting of C1-C4 alkoxy, amido, halogen and aryl.
- the compounds of Formula I may be prepared by an enantioselective route that permits three points of structural diversity; R 1 , R 2 , and Nu, as defined herein.
- the first step is the introduction of the Rl group to the intermediate compound (7) - the synthesis of which is described in Scheme III:
- the preferred reactants are RiCHO and TBSOTf in dichloromethane.
- the next step is the conversion of the Ri containing compound to the following intermediate, by transesterification:
- the epoxide intermediate affords the opportunity for nucleophilic substitution with preferred reagents being TfOH in dichloromethane, followed by BOPCl in pyridine and dichloromethane, to afford the compounds having Formula I:
- Nu in Formula I can R3, defined as for Rl and R2.
- the iodide is quite likely to be a substrate for free-radical based transformations that could introduce an alkyl group.
- organometallic reagents such as organocopper reagents
- organocopper reagents will react either with the epoxide or with the iodide to introduce alkyl.
- the structure of the iodide that intercedes between structures 4 and 5 in the dihydrosalinosporamide route, is as follows:
- Compound 1 is first reacted with 2,2,6-trimethyl-4H-l,3-dioxin-4-one and 2,6-lutidine in refluxing toluene; followed by 2,6-lutidine and TBSOTf in dichloromethane at room temperature, to afford Compound 2.
- Compound 3 is converted to Compound 4 by reaction with TfOCH 2 CH 2 Cl, LDA, and TMSCl in THF at -78C.
- Compound 5 is converted to (+) dihydro-salinosporamide A (Formula II) in two steps, by treatment with: (i) TfOH in CH 2 Cl 2 at -30C; and
- Step 2 Compound 7 is converted into Compound 8 with cyclohexanecarboxaldehyde and TBSOTf in CH 2 Cl 2 at -78C.
- nucleophiles All molecules or ions with a free pair of electrons can act as nucleophiles.
- simple nucleophiles are: H 2 O, NH 3 , OH “ , Cl “ , Br “ , and CN " .
- useful nucleophiles include, but are not limited to amines, hydrazines, alcohols, water, polyamines, polyols, amino alcohols, amino thiols, and dithiols.
- nucleophiles are hydrogen sulfide, thioacetamide, acetamidine, ammonia, carbon monoxide, chloride, bromide, iodide or fluoride ions, bisulfide ion, hydroxyl ion, carbonate (CO 3 ); or acetate (CH 3 CO).
- nucleophiles useful in this invention are grouped into mono-reactive nucleophiles, such as monoamine, hydrazine, and monohydric alcohol reagents, and poly-reactive nucleophiles such as polyamine, amino alcohol, and polyol reagents. Examples of each of these reagents follow.
- Useful amines feature a NH 2 or NH group capable of reacting with the epoxide adducts of the present invention.
- the NH 2 or NH functional group can be attached to linear and/or branched alkanes having from about 1 to 100 carbons.
- the NH 2 , NH, or aminoalkyl groups can also be attached to homocyclic rings such as a cycloalkane having from 3 to about 18 members, aromatic rings, or fused aromatic rings as typified by benzene and naphthalene, respectively; heterocyclic rings, or fused heterocyclic rings having 5 or 6 members consisting of carbon, nitrogen, oxygen and sulfur as typified by pyrrole, furan, thiophene, imidazole, imidazoline, triazole, tetrazole, oxazole, thiazole, thiazoline, indole, benzofuran, benzothiophene, indazole, benzimidazole, benzotriazole, benzoxazole, purine, pyridine, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline, phenathroline;
- Suitable amine reactants can be selected from a wide assortment of heterocycles wherein the reactive NH functional group is actually a member of a heterocyclic ring having from about 3 to about 18 members selected from the group consisting of C, N, O, and S, as exemplified by morpholine and thiomorpholine.
- substituents in all of the above described amines is sometimes desirable, since the substituents of the present invention may impart useful multifunctional properties to the resulting products.
- Useful substituents include: ethers, polyethers,
- R g is defined above, and ⁇ is selected from the group consisting of ethylene, propylene, trimethylene, butylene, and tetramethylene, and x is an integer ranging from 1 to about 10; thioethers and polythioethers (replace O by S in the above formula); carboxy, carboxamide and nitrile groups; sulfur-oxygen substituents such as sulfoxide, sulfone, sulfonic acid, sulfonate ester, sulfonamide, and sulfate groups; phosphorus- oxygen substituents such as phosphoric acid, phosphonic acid, thiophosphoric acid, and thiophosphonic acid groups.
- the presence of these substituents in amine containing alkanes, homocycles, and heterocycles imparts new and useful properties to the additive products.
- Examples of useful amines wherein the amino group is attached to linear and branched alkanes and cycloalkanes, and their substituted derivatives include: methyl, ethyl propyl, butyl, amyl, hexyl, heptyl, octyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, octadecyl, eicosyl, docosyl, and tricosylamine; isopropyl, isobutyl, sec-butyl, tert-butyl, 2-ethyl-propyl, S-(-)-2-methylbutyl, isoamyl, 1,2-dimethylpropYl, tert-amyl, 3,3-dimethylbutyl, 2-heptyl, 3-heptyl, 2-ethylhexyl
- Useful substituted amines include: methoxy, ethoxy, 2-methoxyethyl, 3-methoxypropyl, 3-butoxypropyl, and 3- isopropoxypropylamine; glycine, iminodiacetic acid, sarcosine, alanine, leucine, beta- alanine, 4-aminobutyric acid, 8-amino-caprylic acid, 12-aminododecanoic acid, aspartic acid, glutamic acid, 3-aminoadipic acid, cysteine, penicillamine, homocysteine, S- methylcysteine, ethioneine, asparagine, glutamine, arginine, cyan-amide, 3,3'- iminodipropionitrile, taurine, 3-aminopropanesulfonic acid, 2-aminoethyl- phosphonic acid, 3-aminopropylphosphonic acid, and 6-amino-l-hexylphosphat
- Examples of useful amines wherein an amino group or aminoalkyl group is attached to homocycles such as benzene and fused aromatic rings like naphthalene, and their substituted derivatives include: aniline, 4-methyl- 4-butyl, 4-hexyl-, 4-octyl, 4- decyl, 4-dodecyl, 4-tetradecyl, 4-hexadecyl, 4-cyclohexyl aniline; p-methoxy, 4-butoxy, 4-hexyloxy and 4-methylmercaptoaniline; 5-aminoindan, 5-methoxy-2-methylaniline, 2,4-dimethoxyaniline, 2-aminobiphenyl, 4-phenoxyaniline, 4-(2-aminoethyl) benzenesulfonamide, 1-amino-naphthalene, 2-aminonaphthalene, benzylamine, aminodiphenylmethane, tritylamine, 2,2-diphenylamine,
- Examples of useful amines wherein an amino group or an aminoalkyl group is attached to a heterocycle, a substituted heterocyclic, or a fused heterocycle include: furfurylamine, 2-amino-2-thiophene-carboxylic acid, 3-thiophenemethylamine, 3- aminopyrazole, 2-aminoimidazole, l-(3-aminopropyl)imidazole, hist-amine, histidine, 3- amino- 1 ,2,4-triazole, 3-amino-5-mercapto- 1 ,2,4-triazole, 5-amino-3 -methylisoxazole, muscimol, ibotenic acid, 5-amino-3-me.thyl-isothiazole, 2-aminothiazole, 2-amino-5- phenyl-thiazole, 2-amino-4-phenyl-5-tetradecylthiazole, 2-amino-4-thiazole-acetic acid, 2-amino
- Examples of useful amines wherein the amino group is a member of a heterocyclic ring include: aziridine, 2-methylaziridine, azetidine, pyrrole, pyrrolidine, pyrazole, imidazole, 2-ethyl-imidazole, lH-l,2,3-triazole, 1,2,4-triazole, lH-tetrazole, thi-azolidine, piperidine, 4-methyl piperidine, 4-phenylpiperidine, 4-benzylpiperidine, morpholine, 2,6-dimethylmorpholine, thio-morpholine, hexamethyleneimine, heptamethyleneimine, l-aza-12-crown-4, l-aza-15-crown-5, and l-aza-18-crown-6; substituted heterocycles include pyrrole-2-carboxylic acid, ethyl 4-pyrazole-carboxylate, 2 -mercaptoimidazole,
- Hydrazines Hydrazines useful in the present invention include hydrazine groups attached to alkanes, homocyclics, and heterocyclics as described above. Accordingly, the conversion of many of the above amine derivatives via suitable N-aminating agent, as in the preparation of N-aminoazoles as described in "Advances in Heterocylic Chemistry" volume 53, pages 85-231 (1992), affords useful hydrazines.
- hydrazines examples include hydrazine, 1,1-dimethylhydrazine, 2-hydroxyethylhydrazine, 1- amino-pyrrolidine, N-aminopyrazole, N-aminoindazole, N-aminoimidazole, N- aminobenzimidazole, N-amino-l,2,3-triazole, N-aminobenzotriazole, N-aminotetrazole, N-aminothiazole, thiadiazole, and oxazole; 1-aminopiperidine, 1-aminohoniopiperidine, 4-aminomorpholine, semi-carbazide, carbohydrazide, thiosemicarbazide, 4-ethyl-3- thiosemicarbazide, thiocarbohydrazide, aminoguanidine, 2-hydrazine-2-imid-azoline, phenylhydrazine, 1,1-diphenylhydrazine, 4-methoxy
- Monohydric alcohols useful in the present invention include hydroxy alkanes, hydroxy and hydroxyalkyl containing homocycles, and heterocycles as well as their substituted derivatives by analogy with the amines described above.
- alkanols and substituted alkanols include butyl, hexyl, octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, eicosyl, docosyl, hexacosyl and triacontanyl alcohol; 2-methyl-l-pentyl, 2-propyl-l-pentyl, 3,7-dimethyl-l -octyl alcohol; 2-hexyl, 2-octyl, 4-decyl, 2-dodecyl, 2-hexadecyl alcohol; useful alicyclic alcohols include cyclopropylmethyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, dicyclohexylmethyl, cycloheptyl, cycloheptylmethyl, cyclooctyl, cyclododec
- Useful polyamines and substituted polyamines feature two or more amino groups selected from NH 2 and/or NH-R (R as defined above) which are capable of reacting with the epoxides of the present invention.
- the amine groups can be attached to alkanes, homocycles, and heterocycles; in addition, the polyamine derivatives may also contain one or more substituents
- Useful polyamines feature two or more amino radicals such as NH 2 and/or NH, and are attached to alkanes or branched alkanes containing from about 2 to about ten thousand carbons.
- Other useful polyamines are those where the amino or aminoalkyl groups are attached to a homocycle, a heterocycle; or, wherein the NH groups of the polyamine are members of a heterocyclic ring having from about 6 to about 30 members.
- the cyclic polyamines may contain other heteroatoms such as oxygen and sulfur.
- substituents in the polyamine can impart useful multifunctional properties to the end products. Accordingly, substituents selected from: carboxylic acid, carboxamide and nitrile groups, as well as sulfur-oxygen groups, and phosphorus-oxygen groups are useful. Also useful are ethers, polyethers, thioethers, and polythioethers.
- polyamines bearing alkane and substituted alkane groups include: ethylenediamine (EDA), l,3-propanediamine(PDA), 1, 2-propanediamine, 1,4- butanediamine, 2-methyl-l,2-propane-diamine, 1,3-pentanediamine, 1,5-pentane- diamine, 2,2-dimethyl-l,3-propanediamine, 1,6-hexane-di-amine, 2-methyl-l,5-pentane- di-amine, 1,7-heptanediamine, N-methyl-EDA, N-ethyl-EDA, N,N-dimethyl-EDA, N,N- diethyl-EDA, N,N-dibutyl-EDA, N-methyl-PDA, N-propyl-PDA, N,N-dimethyl-PDA, N,N-diethyl-PDA, N,N-dibutyl-PDA, diethylenetriamine (DETA), N-
- substituted polyamines include: ornithine, lysine, lanthionine, cystine, penicillamine disulfide, and diamino-pimelic acid.
- polyamines containing homocyclic and heterocyclic groups, and substituted groups include: 4,4'-methylene-bis(cyclohexylamine), 1,2- diaminocyclohexane, 1,4-di-aminocyclohexane, l ⁇ -cyclohexane-bis ⁇ methylamine), 1,4- cyclo-hexane-bis-(methylamine), N-cyclohexyl-PDA, and 1,3-adamantane-diamines; substituted aromatic polyamines: benzidine, 1,2-dianilinoethane, 2-aminophenyl disulfide, 4,4'-ethylenedianiline, 3,3'-methylenedianiline, 4,4'-methylenedianiline, o- tolidine, 4-aminophenyl disulfide, 3,3',5,5'-tetramethylbenzidine, 1,2-phenylenediamine, 3,3'-diaminobenzidine, 4-methoxy-l,
- heterocycles wherein one or more of the NH groups of the polyamine are ring members include: l-(2-aminoethyl)piperidine, 3-amino-piperidine, A- aminomethyl-piperidine, 4-amino-2,2,6,6-tetramethyl piperidine, piperazide, 1- methylpiperazine, 1,4-diaminopiperazine, l-(2-aminoethyl)-piperazine, l,4-bis-(3- aminopropyl)-piperazine, tetra-hydro-pyrimidine, homopiperazine, 1,4,7- triazacyclononane,l,5,9-triazacyclo-dodecane, cyclen, 1,4,8,11-tetra-aza- cyclotetradecane, 1,4,-8, 12-tetraazacyclopentadecane, hexacyclen, 4-(2-aminoethyl) morpholine, 4-(3-aminoeth
- substituted polyamines containing polyether groups capable of complexing with alkali and alkaline earth metals include: polyoxyethylene diamines, polyoxypropylene diamines, and polyoxypropylene triamines.
- Amino alcohols are also effective nucleophiles.
- Useful amino alcohols and substituted amino alcohols feature one or more amino groups selected from NH2 and/or NH-R radicals (where R is as defined above), and one or more OH groups capable of reacting with one or more adducts of the present invention.
- Amino alcohol reagents used in designing effective dispersants feature amino radicals such as NH2 and/or NH, and one or more OH radicals attached to alkanes or branched alkanes containing from about 2 to about a hundred carbons.
- amino and aminoalkyl groups present in amino alcohol reactants can be attached to alkanes, homocycles, and heterocycles; moreover, each class of amino alcohol may contain one or more substituents.
- Examples of aliphatic amino alcohols, and substituted derivatives include: ethanolamine, 3-amino-l-propanol, 2-amino-l-pro-panol, 4-amino-l-butanol, 2-amino-l- butanol, 2-amino-2-methyl-l-propanol, 5-amino-l-pentanol, 2-amino-l-pentanol, 2- amino-3-meth-yl-l-butanol, 6-amino-l-hexanol, 2-amino-l-hexanol, isoleucinol, leucinol, serinol, 1 -amino- 1-cyclopentanemethanol, 2-aminocyclo-hexanol, 4-amino- cyclo-hexanol, 1-aminomethyl-cyclo-hexanol, 3-aminomethyl-3,5,5-trimethyl- cyclohexanol, 2-[
- amino alcohols and alkane amino alcohols con-taining homocyclic and heterocyclic groups include: 2-amino-phenol, 2-amminobenzylamine, 2- aminophenethanol, 4-aminophen-ethanol, 2,3-diaminophenol, 4-aminoresorcinol, 2,4- diaminophenol, l-amino-2-naphthol, 2-amino-l-phenylethanol, 2-phenylglycinol, norephedrine, pseudoephedrine, ephedrine, 2-amino-l -phenyl- 1,3 -propanediol, S-benzyl- L-cysteinol, tyramine, octopamine, syn-ephrine, thiomicamine, 3,4-dihydroxybenzyl- amine, epinephrine, dopamine, propranolol, tyrosine, dopa, 3-phenylserine, do
- polyols bearing alkane, and cycloalkane groups include: ethylene glycol, 1,3-propane, 1,2-propane, 2,3-butane, 1,5-pentane, 2,4-pentane, 3, 3 -dimethyl- 1,2- butane, 1,6-hexane, 2,5-hexane, 2-ethyl-l,3-hexane, 1,8-octane, 1,2-octane, 1,10-decane, 1,2-decane, 1,14-tetradecane, 1,2-tetradecane and 1,16-hexadecane-diol; glycerol, 1,1,1- tris-(hydroxymethyl)-ethane, 1,2,3-heptane-triol, pentaerythritol (PE), threitol, erythritol, xylitol, ribose, fructose, glucose, 1,2-cyclopentan
- Useful substituted polyols include: 3-methoxy-l,2-propanediol, diethylene glycol, dipropylene glycol, batyl alcohol, Methylene glycol, tripropylene glycol, tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, dipentaerythritol, tripenterythritol, 1,2- dithiane-4,5-diol, l,5-dithiacyclooctan-3-ol, l,5,9,13,-tetrathiacyclohexadecane-3,l 1-diol, and 1, 5,9,13, 17,21-hexathia-cyclotetracosane-3,l l,19-triol; gluconic acid, tartaric acid, mucic acid, quinic acid, shikimic acid, and ascorbic acid.
- polyols are those wherein the hydroxy or hydroxyalkyl groups are attached to a homocycle or a heterocycle.
- polyols containing homocyclic and heterocyclic groups, and cyclic groups with substituents include: catechol, 4-t- butylcatechol, pyrogallol, resorcinol, olivetol, 2,3-dihydroxy-naphthalene, 4-t-butylcalix- (6)-arene, 1,3-benzenedimethanol, 1 -phenyl- 1,2-ethanediol, 2-benzyloxy-l,3- propanediol, 3-hydroxyphenethanol, hydro-quinone bis-(2-hydroxyethyl) ether, 4.4'-thio- diphenol, 2,4-dihydroxy-propiophenone, phloretin, quinalizarin, purpurin, f ⁇ setin, myricetin, 3,5-dihydroxybenzoic acid, gallic acid, and resorcino
- nucleophiles include dithiocarbamates.
- compounds from which such nucleophiles can be formed include but are not limited to the following: sodium diethyldithiocarbamate, sodium dithiocarbamate, sodium N-methyl dithiocarbamate, sodium dimethylcarbamate, sodium N-ethyl dithiocarbamate, and the like.
- the disclosed compounds may be used to treat conditions mediated directly by the proteolytic function of the proteasome such as muscle wasting, or mediated indirectly via proteins which are processed by the proteasome such as NF-kappaB.
- the proteasome participates in the rapid elimination and post-translational processing of proteins (e.g., enzymes) involved in cellular regulation (e.g., cell cycle, gene transcription, and metabolic pathways), intercellular communication, and the immune response (e.g., antigen presentation).
- proteins e.g., enzymes
- proteins e.g., enzymes
- Specific examples discussed below include beta-amyloid protein and regulatory proteins such as cyclins and transcription factor NF-kappaB.
- Treating as used herein includes reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in manner to improve or stabilize the subject's condition.
- beta-AP beta-amyloid protein
- APP amyloid protein precursor
- isoforms of APP are known (695, 751, and 770 amino acids).
- Alternative splicing of mRNA generates the isoforms; normal processing affects a portion of the beta- AP sequence, thereby preventing the generation of beta-AP. It is believed that abnormal protein processing by the proteasome contributes to the abundance of beta-AP in the Alzheimer brain.
- the APP-processing enzyme in rats contains about ten different subunits (22 kDa-32 kDa).
- the 25 kDa subunit has anN-terminal sequence of X-GIn- Asn-Pro-Met-X-Thr-Gly-Thr-Ser, which is identical to the beta-subunit of human macropain.
- Kojima S. et al., Fed. Eur. Biochem. Soc, 1992, 304, 57-60.
- the APP- processing enzyme cleaves at the GIn 15 ⁇ Lysl6 bond; in the presence of calcium ion, the enzyme also cleaves at the Met-1 -Aspl bond, and the Aspl -Ala2 bonds to release the extracellular domain of beta-AP.
- One embodiment is a method of treating Alzheimer's disease, including administering to a subject an effective amount of a compound (e.g., pharmaceutical composition) having a formula disclosed herein.
- a compound e.g., pharmaceutical composition
- Such treatment includes reducing the rate of beta-AP processing, reducing the rate of beta-AP plaque formation, and reducing the rate of beta-AP generation, and reducing the clinical signs of Alzheimer's disease.
- proteasome inhibitors are useful for treating conditions such as cancer, chronic infectious diseases, fever, muscle disuse (atrophy) and denervation, nerve injury, fasting, renal failure associated with acidosis, and hepatic failure. See, e.g., U.S. Patent No. 5,340,736.
- Additional embodiments of the invention therefore encompass methods of; reducing the rate of muscle protein degradation in a cell; reducing the rate of intracellular protein degradation; reducing the rate of degradation of p53 protein in a cell; and inhibiting the growth of p53 related cancers.
- Each of these methods includes the step of contacting a cell (in vivo or in vitro, e.g., a muscle in a subject) with an effective amount of a compound (e.g., pharmaceutical composition) of a formula disclosed herein.
- a cell in vivo or in vitro, e.g., a muscle in a subject
- a compound e.g., pharmaceutical composition
- NF-kappaB a member of the ReI protein family.
- the ReI family of transcriptional activator proteins can be divided into two groups. The first group requires proteolytic processing, and includes p50 (NF- kappaB 1, 105 kDa) and p52 (NF-kappa2, 100 kDa). The second group does not require proteolytic processing, and includes p65 (ReIA, ReI (c-Rel), and ReIB). Both homo- and heterodimers can be formed by ReI family members; NF-kappaB, for example, is a p50- p65 heterodimer.
- NF-kappaB After phosphorylation and ubiquitination of IkappaB and pi 05, the two proteins are degraded and processed, respectively, to produce active NF-kappaB which translocates from the cytoplasm to the nucleus. Ubiquitinated pi 05 is also processed by purified proteasomes. Palombella et al., Cell 1994, 78, 773-785. Active NF-kappaB forms a stereospecific enhancer complex with other transcriptional activators and, e.g., HMG I(Y), inducing selective expression of a particular gene.
- NF-kappaB regulates genes involved in the immune and inflammatory response, and mitotic events.
- NF-kappaB is required for the expression of the immunoglobulin light chain kappa gene, the IL-2 receptor alpha-chain gene, the class I major histocompatibility complex gene, and a number of cytokine genes encoding, for example, IL-2, IL-6, granulocyte colony-stimulating factor, and IFN-beta. Palombella et al., supra.
- Some embodiments of the invention include methods of affecting the level of expression of IL-2, MHC-I, IL-6, IFN-beta or any of the other previously-mentioned proteins, each method including administering to a subject an effective amount of a compound of a formula disclosed herein.
- NF-kappaB also participates in the expression of the cell adhesion genes that encode E-selectin, P-selectin, ICAm, and VCAM-I, Collins, T., Lab. Invest, 1993, 68, 499-508.
- One embodiment of the invention is a method of inhibiting cell adhesion (e.g., cell adhesion mediated by E-selectin, P-selectin, ICAm, or VCAM-I), including contacting a cell with (or administering to a subject) an effective amount of a compound (e.g., pharmaceutical composition) having a formula disclosed herein.
- NF-kappaB also binds specifically to the HIV-enhancer/promoter.
- the HIV regulatory protein Nef of pbj 14 differs by two amino acids in the region which controls protein kinase binding. It is believed that the protein kinase signals the phosphorylation of I-kappaB, triggering IkappaB degradation through the ubiquitin-proteasome pathway. After degradation, NF-kappaB is released into the nucleus, thus enhancing the transcription of HIV. Cohen, J., Science, 1995, 267, 960. Additional embodiments of the invention are a method of inhibiting or reducing HIV infection in a subject, and a method of decreasing the level of viral gene expression, each method including administering to the subject an effective amount of a compound of a formula disclosed herein.
- Complexes including p50 are rapid mediators of acute inflammatory and immune responses. Thanos et al., Cell, 1995, 80, 529-532. Intracellular proteolysis generates small peptides for presentation to T-lymphocytes to induce MHC class I-mediated immune responses.
- the immune system screens for autologous cells that are virally infected or have undergone oncogenic transformation. Additional embodiments of the invention are a method of inhibiting antigen presentation in a cell, including exposing the cell to a compound of a formula described herein, and a method of suppressing the immune system of a subject (e.g., inhibiting transplant rejection), including administering to the subject an effective amount of a compound of a formula described herein.
- the invention provides a method of treating inflammation, wherein the method includes administering to a subject an effective anti-inflammatory amount of a pharmaceutical composition containing a compound of a formula described herein.
- Inflammation can be a primary or secondary response associated with (a) injury such as a cut, laceration, puncture wound, (b) infection (including infected surgical incisions) by one or more viruses, bacteria, mycobacteria, microorganisms, parasites, and fungi, (c) allergies, (d) a disease state, (e) surgery (e.g., transplantation), or (f) a combination thereof.
- allergens are primary inflammatory responses to antigens or allergens.
- Sources of allergens include plants (e.g., grass or tree pollen), animals (e.g., dander, venom, urine, execreta from dogs, cats, insects, and snakes), and fungi.
- plants e.g., grass or tree pollen
- animals e.g., dander, venom, urine, execreta from dogs, cats, insects, and snakes
- fungi fungi.
- allergens such as rye grass, ragweed, and Japanese cedar pollen
- certain foods or food components e.g., eggs, milk, shellfish, strawberries, chocolate
- vaccines e.g., penicillin
- Disease states include rheumatoid arthritis, scleroderma, rheumatic fever, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), diabetes mellitus, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, conjunctiva of the eye, systemic lupus erythematosus, encephalitis, Adult Respiratory Distress Syndrome, psoriasis, emphysema, Alzheimer's disease, and muscular dystrophy.
- inflammatory bowel disease e.g., Crohn's disease and ulcerative colitis
- the invention provides a method of treating inflammation induced by organ or tissue transplantation.
- This method includes administering to a patient who has undergone or is about to undergo transplantation a composition containing a compound having a formula disclosed herein.
- Transplantations include bone marrow, solid organ (e.g., kidney, lungs, heart, pancreas, liver, and skin), or tissues.
- proteasome inhibitors block both degradation and processing of ubquitinated NF-kappaB in vitro and in vivo.
- Proteasome inhibitors also block IkappaB- alpha degradation and NF-kappaB activation, Palombella et al.; and Traenckner et al., EMBO J, 1994, 13, 5433-5441.
- One embodiment of the invention is a method of inhibiting IkappaB-alpha degradation, including contacting the cell with a compound of a formula described herein.
- a further embodiment is a method of reducing the cellular content of NF-kappaB in a cell, muscle, organ, or subject, including contacting the cell, muscle, organ, or subject with a compound of a formula described herein.
- Proteasome inhibitors are also useful for treatment of ischemic or reperfusion injury, particularly for preventing or reducing the size of infarct after vascular occlusion such as occurs during a stroke or heart attack, as described in U.S. Pat. No. 6,271,199.
- Proteasome inhibitors also block proteasome-dependent transformation of protozoan parasites (Gonzalez et al., J. Exp. Med., 1996, 84, 1909. Further embodiments of the invention therefore encompass methods for treating an infarct or a protozoan parasitic disease by administering a compound of a formula disclosed herein.
- a compound of the present invention is administered to prevent or reduce the size of the infarct after vascular occlusion.
- Said compounds can be administered from about 0 to about 10 hours from the occurrence of a stroke in order to treat or reduce neuronal loss following an ischemic event.
- eukaryotic transcription factors that require proteolytic processing include the general transcription factor TFIIA, herpes simplex virus VP 16 accessory protein (host cell factor), virus-inducible IFN regulatory factor 2 protein, and the membrane-bound sterol regulatory element-binding protein 1.
- Other embodiments of the invention are methods for affecting cyclin-dependent eukaryotic cell cycles, including exposing a cell (in vitro or in vivo) to a compound of a formula disclosed herein. Cyclins are proteins involved in cell cycle control. The proteasome participates in the degradation of cyclins. Examples of cyclins include mitotic cyclins, Gl cyclins, (cyclin B).
- cyclins enables a cell to exit one cell cycle stage (e.g., mitosis) and enter another (e.g., division). It is believed all cyclins are associated with p34cdc2 protein kinase or related kinases.
- the proteolysis targeting signal is localized to amino acids 42-RAALGNISEN-50 (destruction box).
- cyclin is converted to a form vulnerable to a ubiquitin ligase or that a cyclin-specif ⁇ c ligase is activated during mitosis. Ciechanover, A., Cell, 1994, 79, 13-21.
- One embodiment of the invention is a method of treating a proliferative disease in a subject (e.g., cancer, psoriasis, or restenosis), including administering to the subject an effective amount of a compound of a formula disclosed herein.
- Chronic or acute inflammation can result from transplantation rejection, arthritis, rheumatoid arthritis, infection, dermatosis, inflammatory bowel disease, asthma, osteoporosis, and autoimmune diseases.
- Rejection or inflammation can occur in transplanted tissues or organs of any type, including heart, lung, kidney, liver, skin grafts, and tissue grafts.
- the invention also encompasses a method of treating cyclin-related inflammation in a subject, including administering to a subject an effective amount of a compound of a formula described herein.
- Additional embodiments are methods for affecting the proteasome-dependent regulation of oncoproteins and methods of treating or inhibiting cancer growth, each method including exposing a cell (in vivo, e.g., in a subject or in vitro) to a compound of a formula disclosed herein.
- HPV- 16 and HPV-18-derived E6 proteins stimulate ATP- and ubiquitin-dependent conjugation and degradation of p53 in crude reticulocyte lysates.
- the recessive oncogene p53 has been shown to accumulate at the nonpermissive temperature in a cell line with a mutated thermolabile El. Elevated levels of p53 may lead to apoptosis.
- proto-oncoproteins degraded by the ubiquitin system examples include c-Mos, c-Fos, and c-Jun.
- One embodiment is a method of treating p53-related apoptosis, including administering to a subject an effective amount of a compound of a formula disclosed herein.
- Treatment of cancer prevents, alleviates, or ameliorates one or more primary or secondary phenomena associated with the initiation, progression, and metastasis of tumors, especially malignant tumors, e.g., a growth of tissue wherein cell multiplication is uncontrolled. Malignant tumors show a greater degree of anaplasia than do benign tumors.
- the invention provides a method of treating cancer including administering to a subject an effective anti-cancer amount of a pharmaceutical composition described herein, wherein the cancer is selected from carcinoma, lymphoma, sarcoma, and myeloma.
- carcinomas include adenocarcinoma, acinic cell adenocarcinoma, adrenal cortical carcinomas, alveoli cell carcinoma, anaplastic carcinoma, basaloid carcinoma, basal cell carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, renaladinol carcinoma, embryonal carcinoma, anometroid carcinoma, fibrolamolar liver cell carcinoma, follicular carcinomas, giant cell carcinomas, hepatocellular carcinoma, intraepidermal carcinoma, intraepithelial carcinoma, leptomanigio carcinoma, medullary carcinoma, melanotic carcinoma, menigual carcinoma, mesometonephric carcinoma, oat cell carcinoma, squamal cell carcinoma, sweat gland carcinoma, transitional cell carcinoma, and tubular cell carcinoma.
- sarcomas examples include ameloblastic sarcoma, angiolithic sarcoma, botryoid sarcoma, endometrial stroma sarcoma, ewing sarcoma, fascicular sarcoma, giant cell sarcoma, giant cell sarcoma, granulocytic sarcoma, immunoblastic sarcoma, juxaccordial osteogenic sarcoma, coppices sarcoma, leukocytic sarcoma (also known as leukemia), lymphatic sarcoma (also known as lympho sarcoma), medullary sarcoma, myeloid sarcoma (also known as granulocytic sarcoma), osteogenic sarcoma, periosteal sarcoma, reticulum cell sarcoma (also known as histiocytic lymphoma), round cell sarcom
- lymphomas examples include Hodgkin's disease and lymphocytic lymphomas, such as Burkitt's, nodular poorly-differentiated lymphocytic (NPDL), nodular mixed lymphocytic (NML), NH (nodular histiocytic), and diffuse lymphomas. Additional carcinomas include neural blastoma, glioblastoma, astrocytoma, melanoma, leiomyo sarcoma, multiple myeloma, and Hemangioma.
- NPDL nodular poorly-differentiated lymphocytic
- NML nodular mixed lymphocytic
- NH nodular histiocytic
- Additional carcinomas include neural blastoma, glioblastoma, astrocytoma, melanoma, leiomyo sarcoma, multiple myeloma, and Hemangioma.
- a tripeptide aldehyde protease inhibitor (benzyloxycarbonyl (Z)--Leu-Leu- leucinal induces neurite outgrowth in PC12 cells at an optimal concentration of 30 nM, Tsubuki et al., Biochem. and Biophys. Res. Comrn., 1993, 196, 1195-1201.
- Peptide aldehydes have been shown to inhibit the chymotryptic activity of the proteasome. Vinitsky et al., 1992, Tsubuki et al., 1993.
- One embodiment of the invention is a method of promoting neurite outgrowth, including administering to the subject a compound of a formula disclosed herein.
- the disclosed compounds are also useful as diagnostic agents (e.g., in diagnostic kits or for use in clinical laboratories) for screening for proteins (e.g., enzymes, transcription factors) processed by the proteasome.
- the disclosed compounds are also useful as research reagents for specifically binding the X/MB1 subunit or alpha- chain and inhibiting the proteolytic activities associated with it. For example, the activity of (and specific inhibitors of) other subunits of the proteasome can be determined.
- the compounds of the invention can be used to determine whether a cellular, developmental, or physiological process or output is regulated by the proteolytic activity of the proteasome.
- One such method includes obtaining an organism, an intact cell preparation, or a cell extract; exposing the organism, cell preparation, or cell extract to a compound of a formula disclosed herein; exposing the compound-exposed organism, cell preparation, or cell extract to a signal, and monitoring the process or output.
- the high selectivity of the compounds disclosed herein permits rapid and accurate elimination or implication of the proteasome in a given cellular, developmental, or physiological process.
- the methods of the invention contemplate treatment of animal subjects, such as mammals (e.g., higher primates, and especially humans).
- the invention encompasses pharmaceutical compositions which include novel compounds described herein, and pharmaceutical compositions which include compounds described and recognized herein as proteasome inhibitors.
- Pharmaceutically acceptable salts maybe formed, for example, with 1, 2, 3, or more equivalents of hydrogen chloride, hydrogen bromide, trifluoroacetic acid, and others known to those in the art of drug formulation.
- Compounds of the invention can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable non-toxic excipients and carriers.
- a pharmaceutical composition of the invention may contain more than one compound of the invention, and/or may also contain other therapeutic compounds not encompassed by the invention, such as antiinflammatory, anti-cancer, or other agents.
- a subject may have more than one type of inflammation, or more than one type of cancer, a combination of allergies, or a mixture of the above conditions for which the disclosed compounds are useful.
- a compound of the invention may be administered in unit dosage form, and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, Pa., 1980).
- the invention also encompasses a packaged drug, containing a pharmaceutical composition formulated into individual dosages and printed instructions for self-administration.
- proteasome inhibitors may be prepared for use in parenteral administration in the form of solutions or liquid suspensions; for oral administration (preferable), particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, gels, oily solutions, nasal drops, aerosols, or mists.
- Formulations for parenteral administration may contain as common excipients sterile water or sterile saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like.
- Controlled release of a compound of the invention may be obtained, in part, by use of biocompatible, biodegradable polymers of lactide, and copolymers of lactide/glycolide or polyoxyethylene/polyoxypropylene.
- Additional parental delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- Formulations for inhalation administration contain lactose, polyoxyethylene-9-lauryl ether, glycocholate, or deoxycholate.
- Formulations for buccal administration may include glycocholate; formulations for vaginal administration may include citric acid.
- the concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration.
- the compounds of this invention may be provided in an aqueous physiological buffer solution containing about 0.1-10% w/v of compound for parenteral administration. Typical dose ranges are from about 0.1 to about 50 mg/kg of body weight per day, given in 1-4 divided doses. Each divided dose may contain the same or different compounds of the invention.
- the dosage will be an effective amount depending on several factors including the overall health of a patient, and the formulation and route of administration of the selected compound(s).
- the effective amount of the active compound used to practice the present invention for treatment of conditions directly or indirectly mediated by the proteasome varies depending upon the manner of administration, the age and the body weight of the subject and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian. Such amount of the active compound as determined by the attending physician or veterinarian is referred to herein as "effective amount.”
- Flash column chromatography was performed as described by Still et al., 1 employing silica gel (60-A pore size, 230-400 mesh, Merck KGA; or 60-A pore size, 32-63 ⁇ m, standard grade, Sorbent Technologies).
- Analytical thin-layer chromatography (TLC) was performed using glass plates pre-coated with silica gel (0.25 mm, 60-A pore size, 230-400 mesh, Merck KGA) impregnated with a fluorescent indicator (254 nm).
- TLC plates were visualized by exposure to ultraviolet light (UV) and/or exposure to eerie ammonium molybdate solution (CAM), ethanolic phosphomolybdic acid (PMA), or an acidic solution of p-anisaldehyde (anisaldehyde) followed by brief heating on a hot plate (-200 0 C, 10-15 s).
- UV ultraviolet light
- CAM eerie ammonium molybdate solution
- PMA ethanolic phosphomolybdic acid
- anisaldehyde an acidic solution of p-anisaldehyde followed by brief heating on a hot plate (-200 0 C, 10-15 s).
- IR Infrared
- tert-Butyldimethylsilyltrifluoromethanesulfonate (2.40 ml, 2.75 g, 10.4 mmol, 2.0 equiv) was added dropwise over 8 min to a stirring solution of 5-(tert-butyl-dimethyl-silanyloxy)-3-methyl-lH-pyrrole-2-carboxylic acid methyl ester (1.4 g, 5.2 mmol, 1.0 equiv) and cyclohexanecarbaldehyde (0.94 ml, 0.87 g, 7.8 mmol, 1.5 equiv) in dichloromethane (100 ml) at -78 0 C.
- Lithium diisopropylamide solution (0.67 M solution in tetrahydrofuran, 0.09 ml, 0.06 mmol, 1.0 equiv) was added dropwise via syringe to a stirred solution of 2-[(tert-butyl-dimethyl-silanyloxy)-cyclohexyl- methyl]-3-methyl-5-oxo-2,5-dihydro-lH-pyrrole-2-carboxylic acid methyl ester (23 mg, 0.06 mmol, 1.0 equiv) in tetrahydrofuran (1.5 ml) at -78 0 C. The reaction mixture was stirred at -78 0 C for 30 min.
- Titanium (IV) isopropoxide (0.30 ml, 0.42 g, 1.5 mmol, 11.5 equiv) was added to a stirred solution of 4- [(tert-butyl-dimethyl-silanyloxy)-cyclohexyl-methyl]-7-(2-chloro-ethyl)-6-oxo-l-oxa-5- aza-spiro[2.4]heptane-4-carboxylic acid methyl ester (60 mg, 0.13 mmol, 1.0 equiv) in 2- trimethylsilanyl-ethanol (1.5 ml), and the resultant solution was heated at 100 °C for 17 h.
- the reaction mixture was allowed to cool to 23 0 C and ethyl acetate (30 ml) and water (20 ml) was added. The resultant solution was stirred for 10 min and filtered through Celite. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (15 ml x 2). The combined organic layers were dried over sodium sulfate and the solids were filtered. The filtrate was concentrated.
- the reaction mixture was stirred at 0 0 C for 1 h, then warmed to 23 °C, and stirred at 23 °C for 3 h.
- the reaction solution was diluted with ethyl acetate (50 ml), and washed with brine solution (10 ml). The organic layer was separated, dried over sodium sulfate and the solids were filtered. The filtrate was concentrated.
- Triethylamine (17 ⁇ l, 12 mg, 0.119 mmol, 1.0 equiv) was added to a solution of 2-[(tert-butyl-dimethyl- silanyloxy)-cyclohexyl-methyl]-4-(2-chloro-ethyl)-3-hydroxy-3-iodomethyl-5-oxo- pyrrolidine-2-carboxylic acid 2-trimethylsilanyl-ethyl ester (80 mg, 0.119 mmol, 1.0 equiv) in ethyl acetate (5.5 ml) at 23 °C, followed by the addition of Raney Nickel solution. Hydrogen balloon was inserted and the resultant heterogeneous solution was vigorously stirred for 2 h.
- Trifluoromethanesulfonic acid (5 ⁇ l, 8.2 mg, 0.055 mmol, 5.0 equiv) was added to a solution of 2-[(tert-butyl-dimethyl-silanyloxy)-cyclohexyl- methyl]-4-(2-chloro-ethyl)-3-hydroxy-3-methyl-5-oxo-pyrrolidine-2-carboxylic acid 2- trimethylsilanyl-ethyl ester (6 mg, 0.011 mmol, 1.0 equiv) in dichloromethane (1 ml, directly taken from solvent bottles, without drying treatment) at -30 0 C.
- the minor diastereoisomer can be readily removed by flash column chromatography in the next step).
- This mixture was purified by flash column chromatography (10% ethyl acetate- dichloromethane initially, grading to 15% ethyl acetate-dichloromethane) to give 5 (56 mg, 45%) as a colorless oil (Note: 10 mg starting 4 was recovered (10%), and the yield is 50% based on recovered starting material.
- Four diastereoisomers was isolated (1:0.31:0.28:0.26, total yield: 84%), and the major diastereoisomer is the desired one).
- Titanium (IV) isopropoxide (1.0 ml) was added to a stirred solution of pantolactone ester 5 (152 mg, 0.317 mmol, 1.0 equiv) in ethanol (4.5 ml), and the resultant solution was heated at 110 0 C for 6 h in microwave.
- the reaction mixture was allowed to cool to 23 0 C and ethyl acetate (60 ml) and water (30 ml) was added.
- the resultant solution was stirred for 10 min and filtered through Celite.
- the organic layer was separated and the aqueous layer was extracted with ethyl acetate (60 ml x 2). The combined organic layers were dried over sodium sulfate and the solids were filtered.
- Trifluoroacetone (0.4 ml) was added via a precooled syringe, followed by the addition of a mixture of sodium bicarbonate (0.273 g, 3.25 mmol, 15.5 equiv) and Oxone (0.644 g, 1.05 mmol, 5.0 equiv).
- the reaction mixture was stirred for 1 h at 0 0 C.
- Water (20 ml) was added and the resultant mixture was extracted with dichloromethane (50 ml).
- the organic layer was separated and the aqueous layer was extracted with dichloromethane (30 ml x 2).
- the combined organic layers were dried over sodium sulfate and the solids were filtered. The filtrate was concentrated. Purification of the residue by flash column chromatography (15% ethyl acetate-hexanes initially, grading to 20% ethyl acetate-hexanes) provided compound 8 (77 mg, 77%).
- Titanium (IV) isopropoxide (0.36 ml, 0.50 g, 1.8 mmol, 11.1 equiv) was added to a stirred solution of 8 (77 mg, 0.162 mmol, 1.0 equiv) in 2-trimethylsilanyl- ethanol (1.8 ml), and the resultant solution was heated at 100 °C for 18 h.
- the reaction mixture was allowed to cool to 23 0 C and ethyl acetate (30 ml) and water (20 ml) was added.
- the resultant solution was stirred for 10 min and filtered through Celite. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (15 ml x 2).
- (i?)-(-)-pantolactone is coupled to the acid to form the ( ⁇ S)-(+)-pantolactone ester under the Mitsunobu condition.
- the triflate ester of (i?)-(-)-pantolactone is coupled to the acid to form the (iS)-(+)-pantolactone ester via a SN2 substitution.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70702105P | 2005-08-10 | 2005-08-10 | |
PCT/US2006/031314 WO2007021897A1 (en) | 2005-08-10 | 2006-08-10 | Analogs of salinosporamide a |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1931679A1 EP1931679A1 (en) | 2008-06-18 |
EP1931679A4 true EP1931679A4 (en) | 2009-07-29 |
Family
ID=37757890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06789692A Withdrawn EP1931679A4 (en) | 2005-08-10 | 2006-08-10 | Analogs of salinosporamide a |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1931679A4 (en) |
WO (1) | WO2007021897A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
AU2005283141B2 (en) | 2004-04-30 | 2012-05-10 | Nereus Pharmaceuticals, Inc. | (3.2.0) heterocyclic compounds and methods of using the same |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
WO2006060676A1 (en) | 2004-12-03 | 2006-06-08 | Dana Farber Cancer Institute | Compositions and methods for treating neoplastic diseases |
US7691896B2 (en) | 2005-08-10 | 2010-04-06 | President And Fellows Of Harvard College | Analogs of salinosporamide A |
US7842814B2 (en) | 2006-04-06 | 2010-11-30 | Nereus Pharmaceuticals, Inc. | Total synthesis of salinosporamide A and analogs thereof |
WO2008095195A2 (en) | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
EP2262812A2 (en) | 2008-03-07 | 2010-12-22 | Nereus Pharmaceuticals, Inc. | Total synthesis of salinosporamide a and analogs thereof |
CN102089312A (en) | 2008-05-12 | 2011-06-08 | 尼瑞斯药品公司 | Salinosporamide derivatives as proteasome inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002572A2 (en) * | 2003-06-20 | 2005-01-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
-
2006
- 2006-08-10 WO PCT/US2006/031314 patent/WO2007021897A1/en active Application Filing
- 2006-08-10 EP EP06789692A patent/EP1931679A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002572A2 (en) * | 2003-06-20 | 2005-01-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
Also Published As
Publication number | Publication date |
---|---|
EP1931679A1 (en) | 2008-06-18 |
WO2007021897A1 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1931679A1 (en) | Analogs of salinosporamide a | |
US11597716B2 (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
US11364248B2 (en) | Compounds that inhibit Mcl-1 protein | |
EP0800390B1 (en) | Cyclopropylpyrroloindole-oligopeptide anticancer agents | |
KR101050700B1 (en) | Calcium receptor modulating compounds and uses thereof | |
US7524883B2 (en) | Eponemycin and epoxomicin analogs and uses thereof | |
EP1737863B1 (en) | 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-iv inhibitors | |
SK278474B6 (en) | Isoindolone derivatives, preparation method thereof and their use as intermediate products | |
US20180319808A1 (en) | Method for producing a spirooxindole derivative | |
US7465720B2 (en) | Proteasome inhibiting β-lactam compounds | |
ES2404411T3 (en) | Manufacturing process of derivatives of neuraminic acid | |
ES2883265T3 (en) | Derivative of 9 element fused ring | |
US7691896B2 (en) | Analogs of salinosporamide A | |
BR112019023918A2 (en) | KINASE INHIBITORS AND USES OF THE SAME | |
CN112300153B (en) | Heterocyclic compound, pharmaceutical composition and application | |
US9856288B2 (en) | Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof | |
PT88260B (en) | METHOD FOR THE PREPARATION OF IMIDAZOPIRIDAZINE DERIVATIVES WITH CYTOTOXIC ACTIVITY | |
AU5958499A (en) | Process and intermediates for growth hormone secretagogues | |
CA2443585A1 (en) | New derivatives of (3,4-a:3,4-c) carbazole, their preparation process, and pharmaceutical compositions that contain them | |
SU795467A3 (en) | Method of preparing uracyl derivatives | |
CA3177298A1 (en) | Compounds containing benzosultam as erk inhibitors | |
AU2021301417B2 (en) | Aminopyrimidinyl derivatives | |
EP0719777A2 (en) | N-oxotetrahydro-beta-carbolines | |
US20230321108A1 (en) | Unit dosage composition of akt inhibitor | |
US20210171506A1 (en) | Process for Manufacturing Pibrentasvir Active Drug Substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080327 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090630 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 29/00 20060101ALI20090624BHEP Ipc: A61K 31/407 20060101ALI20090624BHEP Ipc: C07D 491/044 20060101AFI20070403BHEP |
|
17Q | First examination report despatched |
Effective date: 20091117 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110503 |